Clinical Study
Role of Genetic Polymorphisms of Deoxycytidine Kinase and Cytidine Deaminase to Predict Risk of Death in Children with Acute Myeloid Leukemia
Table 2
Initial characteristics and clinical outcomes of 27 pediatric patients with AML.
| Number of patients | 27 | Age, median (yr), range | 5.9 (0.05–16.5) | Sex | | Male | 11 (40.74) | Female | 16 (59.26) | Total blood counts | | Leucocytes, median (range)/uL | 23,000 (3,100–254,000) | Platelets, median (range)/uL | 36,000 (3,000–152,000) | Hemoglobin, median (range) g/dL | 6.8 (2.8–13.0) | WBC, >100,000/uL, (%) | 8 (29.6) | CNS positive, (%) | 2 (7.4) | FAB, (%) | | M1 | 9 (33.3) | M2 | 7 (25.9) | M4 | 8 (29.6) | M5 | 1 (3.7) | M6 | 2 (7.4) | M7 | 0 | Remission | | After the first induction course (%) | 20 (74.1) | After the second induction course (%) | 1 (3.7) | Nonresponders (%) | 3 (11.1) | Not assessed | 3 (11.1) | Relapses (%) | 5 (18.5) | Deaths (%) | 13 (48.1) | Early deaths | (38.4) | Treatment-related | 8 (61.5) | Leukemia-related | 5 (38.5) |
|
|